Stock Ratings / Health Care / NCEL / options

CTXR (49) JAGX (31) RADX (61) OPTH (49) ⌘ Pro Terminal →

NewcelX Ltd. (NCEL) Options Positioning, Max Pain & Unusual Sweeps

$2.69 -0.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

NewcelX Ltd. (NCEL) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $15.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NCEL)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (NCEL)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for NCEL.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NCEL)

✓Walkthrough of NCEL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NCEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -39.00%▼ DESCENDING CHANNEL

2026-10-30O $2.59H $2.75L $2.50C $2.69VOL 11.2K

RES: $3.16SUP: $2.20SMA50: $3.03SMA200: $3.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NCEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NCEL Butterfly Map → + Track NCEL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NCEL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NCEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NCEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NCEL)

Health Care Rank #684 of 1016 ⚔️ CTXR vs NCEL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NCEL vs. CTXR, JAGX, RADX, OPTH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NewcelX Ltd. (NCEL) ranks #684 by composite RQD confidence (39/100, grade D-) and #857 by equity capitalization ($15.5M). Within this direct 5-issuer industry benchmark cohort, NCEL leads on earnings valuation at N/A trailing P/E, while NCEL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RADX currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with NCEL at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NCEL ACTIVE NewcelX Ltd.	D-	39/100	—	—	-35.0%	-0.30%	$15.5M	Benchmark Subject
CTXR Citius Pharmaceuticals Inc.	D	49/100	—	—	-35.0%	+4.07%	$15.5M	/ctxr-vs-ncel →
JAGX Jaguar Health Inc.	E	31/100	—	67.2%	-35.0%	-2.86%	$15.9M	/jagx-vs-ncel →
RADX Radiopharm Theranostics Limited	C-	61/100	—	—	—	+17.52%	$16.1M	/radx-vs-ncel →
OPTH Optimi Health Corp.	D	49/100	—	—	—	-6.81%	$14.9M	/opth-vs-ncel →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001783036

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NewcelX Ltd. (NCEL) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.3M, operating cash flow of -$2.8M, and free cash flow of -$2.8M (-158.8% YoY). On the balance sheet, NCEL closed FY2025 with $11.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$8.3M	-$2.8M	-$2.8M	$11.4M	—
FY2024 (FY)	2024-12-31	$0	-$7.2M	-$1.1M	-$1.1M	$903.0K	—
FY2023 (FY)	2023-12-31	$0	-$3.3M	-$3.4M	-$3.4M	—	—

3. NCEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, NewcelX Ltd. (NASDAQ: NCEL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $2.69 (-0.30% 1D, market cap $15.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NCEL ranks #684 in composite RQD confidence.

How does NCEL compare to CTXR and JAGX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NCEL carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CTXR (Citius Pharmaceuticals Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $15.5M) and JAGX (Jaguar Health Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.9M). Among the 5-stock peer group, NCEL leads on earnings multiple (N/A) while NCEL leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NCEL?

Per NCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001783036), NewcelX Ltd. generated $0 in revenue, -$8.3M in net income, and -$2.8M in free cash flow against $11.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NCEL trading relative to its 50-day, 200-day, and 52-week technical levels?

NCEL last traded at $2.69 (-0.30% on volume of 1,720 shares), positioning the stock -11.22% below its 50-day simple moving average ($3.03) and -13.23% below its 200-day simple moving average ($3.10). Across its 52-week range of $1.83 to $6.48, NCEL sits at the 18.5% percentile with a 14-day RSI of 42.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.35 to $3.03).

NCEL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NCEL's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for NCEL.

Direct Sub-Reports: NCEL RQD Cockpit NCEL 12M Forecast NCEL Earnings & Move NCEL Dividends & DRIP NCEL Insiders & 13F NCEL Whale Options NCEL Profit Sankey NCEL News & Why